Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Warm compresses vs. High-Tech eye gadgets: which best treats dry eye?

NCT ID NCT05577910

Symptom relief Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested three treatments for meibomian gland dysfunction, a common cause of dry eye. 374 adults with mild-to-moderate dry eye were randomly assigned to receive either vectored thermal pulsation (a device that heats and massages the eyelids), intense pulsed light therapy combined with gland expression, or standard warm compresses. The goal was to see which treatment improves tear film stability and symptoms over 15 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vectored thermal pulsation (LipiFlow), intense pulsed light (Lumenis M22) with meibomian gland expression, and eyelid warm compress therapy
What this could lead to
If successful, this could identify which of these treatments works best for dry eye caused by blocked eyelid glands, potentially improving comfort and eye health.
What could go wrong
This is a completed trial, but results may not apply to everyone with dry eye. The treatments are compared to warm compresses, not a placebo, so differences may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

374 people

The number who actually took part.

Started

Oct 2022

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years of age with no upper age limit; 2. Agree to attend follow-up visits and comply to treatment regimen; 3. Symptomatic dry eye TFBUT (average of 3 times) ≤ 5 seconds and OSDI ≥ 13; 4. Mild to moderate (level 3-4) MGD on at least one eye; 5. Fitzpatrick skin type 1-4. Exclusion Criteria: 1. Contact lens wear 3 months before or during the study period; 2. Use of topical (including anti-glaucomatous, cyclosporin, antibiotics) or systemic medication known to affect (worsen or improve) MGD 3 months before or during the study period; 3. Major systemic (e.g. Sjogren's syndrome), dermatologic (e.g. Rosacea) known to affect MGD or ocular conditions (including thyroid eye disease, recurrent conjunctivitis, ocular allergies); 4. Ocular procedures (excluding uncomplicated cataract operation) 3 months before and any ocular procedure during the study period; 5. History of vision correction surgery or plan to undergo the procedure during the study period; 6. Dermatological treatment (including chemical peeling, laser, IPL or energy device in the periocular and facial region) 6 months before or during the study period; 7. Contraindications to IPL therapy (including recent sun-burn, photosensitivity, active or pigmented skin lesions, cancer, implants, tattoos, semi-permanent makeup in the periocular area); 8. Contraindications to VTP therapy (ocular surgery, ocular injury, ocular herpes of eye or eyelid, and ocular inflammation 3 months before the study; active ocular infection, etc.) 9. Women who are pregnant, nursing, planning pregnancy, or of childbearing potential not using a reliable method of contraception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meibomian gland dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome Meibomian Gland Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meibomian gland dysfunction

Contacts and locations

Locations

  • Hong Kong Eye Hospital

    Kowloon, Hong Kong, Hong Kong

  • Prince of Wales Hospital

    Shatin, 000000, Hong Kong

  • The CUHK Medical Centre (CUHKMC)

    Shatin, 000 000, Hong Kong

  • The Chinese University of Hong Kong Eye Centre (CUHKEC)

    Kowloon, 000000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.